LivaNova Receives FDA Approval for aura6000 System to Treat Obstructive Sleep Apnea
LivaNova announced the FDA granted premarket approval for the aura6000 System for the treatment of adult patients with moderate to severe Obstructive Sleep Apnea. The System utilizes proximal hypoglossal nerve stimulation, a differentiated neurostimulation modality, to treat OSA in patients with an apnea-hypopnea index between 15 and 65 and who have failed, do not tolerate, or are ineligible for first-line therapies, such as positive airway pressure.
